Juan Nieves-Rivera, MD
Cardiovascular Disease · Arecibo, PRNPI 1588929624
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,750 of the $50,004 with a category attached, or 63.5%. Johnson & Johnson accounts for 68.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $21,832 and has fallen 94.8% since, to $1,131 in 2025. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $152.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$34K
- Abbott$4K
- Biotronik Inc.$3K
- Medtronic$2K
- Merck$1K
- Boston Scientific$949
- plus $5K from 18 others
What the payments were for
- Consulting fees$2,3005%
- Speaking & faculty fees$31,75063%
- Travel & lodging$4,0878%
- Food & beverage$11,70223%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 50 | $34,006 |
| Abbott | 45 | $4,055 |
| Biotronik Inc. | 7 | $2,672 |
| Medtronic(2 entities) | 25 | $2,298 |
| Merck | 11 | $1,170 |
| Boston Scientific | 22 | $949 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $901 |
| E.r. Squibb & Sons, L.L.C. | 36 | $847 |
| AstraZeneca | 30 | $833 |
| Boehringer Ingelheim | 25 | $761 |
| PBG Puerto Rico LLC | 14 | $301 |
| Amgen | 11 | $179 |
| Astellas Pharma US Inc | 8 | $172 |
| United Therapeutics Corporation | 3 | $169 |
| Akcea Therapeutics, Inc. | 5 | $165 |
| Bayer | 1 | $125 |
| Bridgebio Pharma, Inc. | 1 | $105 |
| Actelion Pharmaceuticals US, Inc. | 4 | $98 |
| Chiesi USA, Inc. | 1 | $81 |
| Novartis | 2 | $45 |
| Dexcom, Inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Pfizer Pharmaceuticals LLC | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$33,211
- CardioMEMS HF System$1,107
- STEGLATRO$950
- HeartMate 3 Left Ventricular Dev$922
- Micra$510
- HeartMate PHP$361
- Amplia MRI$271
- FARXIGA$250
- CoreValve Evolut$236
- LifeVest$200
- Cobalt$168
- COREVALVE EVOLUT R$148
- GENERAL ATHERECTOMY$147
- ENDURANT IIS$133
- COBALT DR MRI SURESCAN$130
- ORENITRAM$125
- EMBLEM MRI S-ICD$116
- Allure CRT Pacemaker$114
- VISA AF MRI VR SURESCAN$110
- Attruby$105
How this compares
$50,004 in reported general payments places this provider in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 14 | $322,391 |
| FarxigaDapagliflozin Propanediol | 435 | $301,156 |
| EliquisApixaban | 427 | $266,073 |
| EntrestoSacubitril/Valsartan | 341 | $244,840 |
| XareltoRivaroxaban | 296 | $204,507 |
| JardianceEmpagliflozin | 135 | $102,485 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 292 | $52,481 |
| Candesartan Cilexetil | 271 | $37,181 |
| BrilintaTicagrelor | 72 | $33,377 |
| Metoprolol Succinate | 1,272 | $25,057 |
| Rosuvastatin Calcium | 1,614 | $23,111 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 719 | $17,768 |
| Losartan Potassium | 1,308 | $17,726 |
| Atorvastatin Calcium | 1,159 | $14,670 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 251 | $12,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $13 | $588,464441 claims |
| AstraZenecaFarxiga, Brilinta | $833 | $334,533507 claims |
| NovartisEntresto | $45 | $244,840341 claims |
| Johnson & JohnsonXarelto | $34,006 | $204,507296 claims |
| Boehringer IngelheimJardiance | $761 | $102,485135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Arecibo
- Jorge Ballester MaldonadoArecibo$12K
- Victor Salgado BravoArecibo$9K
- Suely Roman LopezArecibo$8K
- Karen Rodriguez MaldonadoMayaguez$231K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
- Luis Rosado CarrilloGuaynabo$173K
- Jorge GonzalezCaguas$114K
- Luis GelyCaguas$89K
- Luis Renta RosaCarolina$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.